Search

Your search keyword '"Meriranta, Leo"' showing total 36 results
Start Over Author "Meriranta, Leo"
36 results on '"Meriranta, Leo"'

4. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Author

Meriranta, Leo, Alkodsi, Amjad, Pasanen, Annika, Lepistö, Maija, Mapar, Parisa, Blaker, Yngvild Nuvin, Jørgensen, Judit, Karjalainen-Lindsberg, Marja-Liisa, Fiskvik, Idun, Mikalsen, Lars Tore G., Autio, Matias, Björkholm, Magnus, Jerkeman, Mats, Fluge, Øystein, Brown, Peter, Jyrkkiö, Sirkku, Holte, Harald, Pitkänen, Esa, Ellonen, Pekka, and Leppä, Sirpa

Published
2022
Full Text
View/download PDF

5. Immunogenomic Landscape of Hematological Malignancies

Author

Dufva, Olli, Pölönen, Petri, Brück, Oscar, Keränen, Mikko A.I., Klievink, Jay, Mehtonen, Juha, Huuhtanen, Jani, Kumar, Ashwini, Malani, Disha, Siitonen, Sanna, Kankainen, Matti, Ghimire, Bishwa, Lahtela, Jenni, Mattila, Pirkko, Vähä-Koskela, Markus, Wennerberg, Krister, Granberg, Kirsi, Leivonen, Suvi-Katri, Meriranta, Leo, Heckman, Caroline, Leppä, Sirpa, Nykter, Matti, Lohi, Olli, Heinäniemi, Merja, and Mustjoki, Satu

Published
2020
Full Text
View/download PDF

7. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Author

Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, de Nully Brown, Peter, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald

Published
2020
Full Text
View/download PDF

8. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma

Author

Meriranta, Leo, primary, Sorri, Selma, additional, Huse, Kanutte, additional, Liu, Xiaonan, additional, Spasevska, Ivana, additional, Zafar, Sadia, additional, Chowdhury, Iftekhar, additional, Dufva, Olli, additional, Sahlberg, Eerika, additional, Tandaric, Luka, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Hyytiainen, Marko, additional, Varjosalo, Markku, additional, Myklebust, June H., additional, and Leppa, Sirpa, additional

Published
2024
Full Text
View/download PDF

10. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Author

Reddy, Anupama, Zhang, Jenny, Davis, Nicholas S., Moffitt, Andrea B., Love, Cassandra L., Waldrop, Alexander, Leppa, Sirpa, Pasanen, Annika, Meriranta, Leo, Karjalainen-Lindsberg, Marja-Liisa, Nørgaard, Peter, Pedersen, Mette, Gang, Anne O., Høgdall, Estrid, Heavican, Tayla B., Lone, Waseem, Iqbal, Javeed, Qin, Qiu, Li, Guojie, Kim, So Young, Healy, Jane, Richards, Kristy L., Fedoriw, Yuri, Bernal-Mizrachi, Leon, Koff, Jean L., Staton, Ashley D., Flowers, Christopher R., Paltiel, Ora, Goldschmidt, Neta, Calaminici, Maria, Clear, Andrew, Gribben, John, Nguyen, Evelyn, Czader, Magdalena B., Ondrejka, Sarah L., Collie, Angela, Hsi, Eric D., Tse, Eric, Au-Yeung, Rex K.H., Kwong, Yok-Lam, Srivastava, Gopesh, Choi, William W.L., Evens, Andrew M., Pilichowska, Monika, Sengar, Manju, Reddy, Nishitha, Li, Shaoying, Chadburn, Amy, Gordon, Leo I., Jaffe, Elaine S., Levy, Shawn, Rempel, Rachel, Tzeng, Tiffany, Happ, Lanie E., Dave, Tushar, Rajagopalan, Deepthi, Datta, Jyotishka, Dunson, David B., and Dave, Sandeep S.

Published
2017
Full Text
View/download PDF

12. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, primary, Jørgensen, Judit M., additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Mette, additional, Drott, Kristina, additional, Pasanen, Annika, additional, Karihtala, Kristiina, additional, Mannisto, Susanna, additional, Meriranta, Leo, additional, Wold, Bente, additional, Brodtkorb, Marianne, additional, Fagerli, Unn Merete, additional, Larsen, Thomas S., additional, Munksgaard, Lars, additional, Sunela, Kaisa, additional, Fluge, Øystein, additional, Jyrkkio, Sirkku, additional, Brown, Peter de Nully, additional, and Holte, Harald, additional

Published
2022
Full Text
View/download PDF

13. Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Author

Arffman, Maare, primary, Meriranta, Leo, additional, Holte, Harald, additional, Jørgensen, Judit, additional, Brown, Peter De Nully, additional, Jyrkkio, Sirkku, additional, Jerkeman, Mats, additional, Fluge, Øystein, additional, Björkholm, Magnus, additional, Autio, Matias, additional, Leivonen, Suvi-Katri, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

14. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Author

Jerkeman, Mats, primary, Kolstad, Arne, additional, Hutchings, Martin, additional, Pasanen, Annika, additional, Meriranta, Leo, additional, Niemann, Carsten Utoft, additional, Rask Kragh Jørgensen, Rasmus, additional, El-Galaly, Tarec Christoffer Christoffer, additional, Riise, Jon, additional, Leppä, Sirpa, additional, Christensen, Jacob Haaber, additional, Wader, Karin Fahl, additional, and Glimelius, Ingrid, additional

Published
2022
Full Text
View/download PDF

18. The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma

Author

Isaksen, Kathrine T., primary, Beiske, Klaus, additional, Smeland, Erlend B., additional, Jørgensen, Judit, additional, Brodtkorb, Marianne, additional, Myklebust, June Helen, additional, Jerkeman, Mats, additional, Meriranta, Leo, additional, Karjalainen‐Lindsberg, Marja‐Liisa, additional, Leppä, Sirpa, additional, Scott, David W., additional, Holte, Harald, additional, and Blaker, Yngvild Nuvin, additional

Published
2020
Full Text
View/download PDF

19. Diffuusin suurisoluisen B-solulymfooman nykyhoito

Author

Leppä, Sirpa, Meriranta, Leo, Pasanen, Annika, Jyrkkiö, Sirkku, Syöpätautien osasto, HUS Syöpäkeskus, Tutkimusohjelmayksikkö, and Helsingin yliopisto

Subjects
3122 Syöpätaudit
Abstract

Teema : Hematologiset syövät. English summary

Published
2019

21. Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Author

Meriranta, Leo, primary, Alkodsi, Amjad, additional, Pasanen, Annika, additional, Lepistö, Maija, additional, Blaker, Yngvild Nuvin, additional, Autio, Matias, additional, Jørgensen, Judit, additional, Jerkeman, Mats, additional, Holte, Harald, additional, Ellonen, Pekka, additional, and Leppa, Sirpa, additional

Published
2019
Full Text
View/download PDF

22. The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Author

Isaksen, Kathrine T., primary, Beiske, Klaus, additional, Smeland, Erlend B., additional, Jørgensen, Judit, additional, Brodtkorb, Marianne, additional, Myklebust, June Helen, additional, Jerkeman, Mats, additional, Meriranta, Leo, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Leppa, Sirpa, additional, Scott, David W., additional, Holte, Harald, additional, and Blaker, Yngvild Nuvin, additional

Published
2019
Full Text
View/download PDF

24. Immunogenomic landscape of hematological malignancies

Author

Dufva, Olli, primary, Pölönen, Petri, additional, Brück, Oscar, additional, Keränen, Mikko, additional, Mehtonen, Juha, additional, Kumar, Ashwini, additional, Heckman, Caroline, additional, Siitonen, Sanna, additional, Granberg, Kirsi, additional, Leivonen, Suvi-Katri, additional, Meriranta, Leo, additional, Leppä, Sirpa, additional, Nykter, Matti, additional, Lohi, Olli, additional, Heinäniemi, Merja, additional, and Mustjoki, Satu, additional

Published
2019
Full Text
View/download PDF

25. The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma.

Author

Isaksen, Kathrine T., Beiske, Klaus, Smeland, Erlend B., Jørgensen, Judit, Brodtkorb, Marianne, Myklebust, June Helen, Jerkeman, Mats, Meriranta, Leo, Karjalainen‐Lindsberg, Marja‐Liisa, Leppä, Sirpa, Scott, David W., Holte, Harald, and Blaker, Yngvild Nuvin

Published
2021
Full Text
View/download PDF

26. Immunogenomic Landscape of Hematological Malignancies

Author

Dufva, Olli, primary, Pölönen, Petri, additional, Brück, Oscar, additional, Keränen, Mikko A, additional, Mehtonen, Juha, additional, Siitonen, Sanna M., additional, Leivonen, Suvi-Katri, additional, Meriranta, Leo, additional, Leppa, Sirpa, additional, Nykter, Matti, additional, Lohi, Olli, additional, Heinäniemi, Merja, additional, and Mustjoki, Satu, additional

Published
2018
Full Text
View/download PDF

27. Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Author

Leppa, Sirpa, primary, Jørgensen, Judit, additional, Meriranta, Leo, additional, Beiske, Klaus, additional, Delabie, Jan M.A., additional, Ralfkiaer, Elisabeth, additional, Spetalen, Signe, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, and Holte, Harald, additional

Published
2018
Full Text
View/download PDF

29. Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma

Author

Meriranta, Leo, primary, Pasanen, Annika, additional, Louhimo, Riku, additional, Cervera, Alejandra, additional, Alkodsi, Amjad, additional, Autio, Matias, additional, Taskinen, Minna, additional, Rantanen, Ville, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Holte, Harald, additional, Delabie, Jan, additional, Lehtonen, Rainer, additional, Hautaniemi, Sampsa, additional, and Leppä, Sirpa, additional

Published
2017
Full Text
View/download PDF

30. Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Author

Zhang, Jenny, primary, Reddy, Anupama, additional, Love, Cassandra, additional, Moffitt, Andrea B., additional, Rajagopalan, Deepthi, additional, Leppä, Sirpa, additional, Pasanen, Annika, additional, Meriranta, Leo, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Norgaard, Peter H, additional, Pederson, Mette, additional, Ortved Gang, Anne, additional, Hogdall, Estrid, additional, Richards, Kristy L., additional, Fedoriw, Yuri D., additional, Bernal-Mizrachi, Leon, additional, Koff, Jean L., additional, Staton, Ashley D., additional, Flowers, Christopher, additional, Paltiel-Clarfield, Ora, additional, Goldschmidt, Neta, additional, Calaminici, Maria, additional, Clear, Andrew James, additional, Gribben, John, additional, Nguyen, Evelyn, additional, Czader, Magdalena, additional, Ondrejka, Sarah Lynn, additional, Collie, Angela, additional, Hsi, Eric D, additional, au-Yeung, Rex, additional, Yok-Lam, Kwong, additional, Choi, Wai Lap, additional, Srivastava, Gopesh, additional, Evens, Andrew M, additional, Pilichowska, Monika, additional, Sengar, Manju, additional, Reddy, Nishitha, additional, Li, Shaoying, additional, Jaffe, Elaine S., additional, Tzeng, Tiffany, additional, Datta, Jyotishka, additional, Dunson, David, additional, and Dave, Sandeep, additional

Published
2016
Full Text
View/download PDF

32. Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Author

Zhang, Jenny, Reddy, Anupama, Davis, Nicholas, Moffitt, Andrea, Love, Cassandra, Waldrop, Alexander, Leppa, Sirpa, Pasanen, Annika, Meriranta, Leo, Karjalainen-Lindsberg, Marja-Liisa, Norgaard, Peter H., Pedersen, Mette Ø, Gang, Anne Ortved, Hogdall, Estrid, Heavican, Tayla, Lone, Waseem, Iqbal, Javeed, Li, Guojie, Kim, So Young, Healy, Jane, Richards, Kristy L., Fedoriw, Yuri, Bernal-Mizrachi, Leon, Koff, Jean L., Staton, Ashley D., Flowers, Christopher, Paltiel-Clarfield, Ora, Goldschmidt, Neta, Calaminici, Maria, Clear, Andrew James, Gribben, John G., Nguyen, Evelyn, Czader, Magdalena, Ondrejka, Sarah L., Collie, Angela, Hsi, Eric D., Tse, Eric, Au-Yeung, Rex, Kwong, Yok-Lam, Srivastava, Gopesh, Choi, William, Evens, Andrew M, Pilichowska, Monika, Sengar, Manju, Reddy, Nishitha, Li, Shaoying, Chadburn, Amy, Gordon, Leo I., Jaffe, Elaine S., Rempel, Rachel, Tzeng, Tiffany, Dave, Tushar, Happ, Lanie, Rajagopalan, Deepthi, Datta, Jyotishka, Dunson, David, and Dave, Sandeep

Published
2017
Full Text
View/download PDF

33. Somatic Mutations in E3 Ubiquitin Ligase Deltex 1 Are Associated with Survival in Diffuse Large B-Cell Lymphoma

Author

Taskinen, Minna, primary, Meriranta, Leo, additional, Pasanen, Annika, additional, Louhimo, Riku, additional, Cervera, Alejandra, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Holte, Harald, additional, Delabie, Jan, additional, Lehtonen, Rainer, additional, Hautaniemi, Sampsa, additional, and Leppä, Sirpa, additional

Published
2014
Full Text
View/download PDF

34. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcomein high-risk aggressive B-cell lymphoma

Author

Meriranta, Leo, Alkodsi, Amjad, Pasanen, Annika, Lepistö, Maija, Mapar, Parisa, Blaker, Yngvild Nuvin, Jørgensen, Judit, Karjalainen-Lindsberg, Marja-Liisa, Fiskvik, Idun, Mikalsen, Lars Tore G, Autio, Matias, Björkholm, Magnus, Jerkeman, Mats, Fluge, Øystein, Brown, Peter, Jyrkkiö, Sirkku, Holte, Harald, Pitkänen, Esa, Ellonen, Pekka, and Leppä, Sirpa

Abstract

Inadequate molecular and clinical stratification of the patientswith high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalizedtherapeutic options. We studiedthe translational significance of liquid biopsy in a uniformly treated trial cohort.Pretreatment circulating tumor DNA (ctDNA)revealed hiddenclinical and biological heterogeneity, and high ctDNA burdendeterminedincreasedrisk of relapse and deathindependentlyof conventional risk factors. Genomic dissection of pretreatment ctDNA revealed translationally relevantphenotypic, molecular,and prognostic information that extended beyond diagnostic tissue biopsies.During therapy, chemorefractory lymphomas exhibited diverging ctDNA kinetics, whereas end-of-therapy negativity for minimal residual diseasecharacterized cured patientsand resolvedclinical enigmas, including false residual PET positivity.Furthermore, we discovered fragmentation disparities in the cell-free DNA that characterize lymphoma-derived ctDNA and,as a proof-of-conceptfor their clinical application,utilized machinelearningto show that end-of-therapy fragmentation patterns predict outcome. Altogether, wehave discovered novel molecular determinantsin the liquid biopsythatcan non-invasively guide treatment decisions.

Published
2021
Full Text
View/download PDF

36. Clinical significance of gene defects in B-cell lymphomas.

Author

Pasanen A, Meriranta, and Leppä S

Subjects
Humans, Lymphoma, B-Cell therapy, Prognosis, Risk Factors, Gene Expression Profiling, Lymphoma, B-Cell genetics
Abstract

Lymphomas are a heterogenous group of malignant diseases. Identification of sub-groups has created pressure for a more detailed diagnosis and individualized treatment. Although the underlying genetic and molecular pathologic factors of the most common B-cell derived lymphomas, i.e. diffuse large B-cell lymphoma and follicular lymphoma, have become more accurate, prognosis is evaluated and treatment options still selected mainly on the basis of clinical variables. In the future, new generation sequencing methods that are becoming more common in clinical practice will allow the assessment of prognosis and treatment on the basis of biologic and genetic risk factors. To achieve this both comprehensive basic research and clinical drug trials taking the pathogenesis of different diseases into consideration are required.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results